SEC Tracker
Get the app

Inovio Pharmaceuticals INO

Inovio Pharmaceuticals announces Q3 2026 results and VOCERYQ approval

Inovio Pharmaceuticals (INO) filed an 8-K with the SEC on Nov 10, 2026, 4:08 pm ET. Source: the filing on SEC EDGAR.

Item 2.02 Reports results

Form
8-K
Filed
Importance
Major
  1. VOCERYQ granted FDA accelerated approval for RRP on Oct 30, 2026
  2. Net loss of $49.2 million for Q3 2026, up from $45.5 million in Q3 2025
  3. Raised $80.5 million in public offering to support VOCERYQ launch
  4. Cash, cash equivalents, and short-term investments as of Sep 30, 2026

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Get an email when Inovio Pharmaceuticals files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Data on this page was fetched . The filing on SEC.gov is the record.